Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liyan Jiang

Showing results (111-120 of 165) with videos related to

Pageof 17
Sort By:
Experimental and Therapeutic Medicine|September 15, 2012
ERCC1 protein as a guide for individualized therapy of late-stage advanced non-small cell lung cancerZhiqiang Gao, Baohui Han, Jie Shen, et al.
Journal of Cancer|December 1, 2017
Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancerShaohua Cui, Xinying Su, Lili Dong, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|August 26, 2015
KDM6B Elicits Cell Apoptosis by Promoting Nuclear Translocation of FOXO1 in Non-Small Cell Lung CancerJun Ma, Ning Wang, Yurong Zhang, et al.
Cancer Letters|February 1, 2022
Long noncoding RNA LHFPL3-AS2 suppresses metastasis of non-small cell lung cancer by interacting with SFPQ to regulate TXNIP expressionZhuoan Cheng, Chunlai Lu, Hui Wang, et al.
Cancer Biology & Therapy|December 16, 2024
First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectivesQi He, Xiaoyan Liu, Liyan Jiang, et al.
Cancer Letters|August 16, 2016
EGFR regulates iron homeostasis to promote cancer growth through redistribution of transferrin receptor 1Biao Wang, Jiqin Zhang, Fei Song, et al.
Thoracic Cancer|February 21, 2025
Perioperative Treatment in EGFR-Mutant Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Future PerspectivesXiaobei Guo, Xiaoyan Liu, Chao Guo, et al.
BMC Cancer|February 28, 2014
Increased IR-A/IR-B ratio in non-small cell lung cancers associates with lower epithelial-mesenchymal transition signature and longer survival in squamous cell lung carcinomaLiyan Jiang, Wei Zhu, Katie Streicher, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|May 16, 2024
IMpower210: A phase III study of second-line atezolizumab <i>vs.</i> docetaxel in East Asian patients with non-small cell lung cancerYi-Long Wu, Shun Lu, Gongyan Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2011
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancerBaohui Han, Qingyu Xiu, Huimin Wang, et al.
Pageof 17

Showing results (111-120 of 165) with videos related to

Sort By:
Pageof 17
Experimental and Therapeutic Medicine|September 15, 2012
ERCC1 protein as a guide for individualized therapy of late-stage advanced non-small cell lung cancerZhiqiang Gao, Baohui Han, Jie Shen, et al.
Journal of Cancer|December 1, 2017
Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancerShaohua Cui, Xinying Su, Lili Dong, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|August 26, 2015
KDM6B Elicits Cell Apoptosis by Promoting Nuclear Translocation of FOXO1 in Non-Small Cell Lung CancerJun Ma, Ning Wang, Yurong Zhang, et al.
Cancer Letters|February 1, 2022
Long noncoding RNA LHFPL3-AS2 suppresses metastasis of non-small cell lung cancer by interacting with SFPQ to regulate TXNIP expressionZhuoan Cheng, Chunlai Lu, Hui Wang, et al.
Cancer Biology & Therapy|December 16, 2024
First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectivesQi He, Xiaoyan Liu, Liyan Jiang, et al.
Cancer Letters|August 16, 2016
EGFR regulates iron homeostasis to promote cancer growth through redistribution of transferrin receptor 1Biao Wang, Jiqin Zhang, Fei Song, et al.
Thoracic Cancer|February 21, 2025
Perioperative Treatment in EGFR-Mutant Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Future PerspectivesXiaobei Guo, Xiaoyan Liu, Chao Guo, et al.
BMC Cancer|February 28, 2014
Increased IR-A/IR-B ratio in non-small cell lung cancers associates with lower epithelial-mesenchymal transition signature and longer survival in squamous cell lung carcinomaLiyan Jiang, Wei Zhu, Katie Streicher, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|May 16, 2024
IMpower210: A phase III study of second-line atezolizumab <i>vs.</i> docetaxel in East Asian patients with non-small cell lung cancerYi-Long Wu, Shun Lu, Gongyan Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2011
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancerBaohui Han, Qingyu Xiu, Huimin Wang, et al.
Pageof 17